Weinstein S P, Watts J, Graves P N, Haber R S
Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029.
Endocrinology. 1990 Mar;126(3):1421-9. doi: 10.1210/endo-126-3-1421.
We have studied regulation of the glucose transporter by thyroid hormone in ARL 15 cells, a thyroid hormone-responsive cell line derived from rat liver, T3 treatment (5 x 10(-8) M for 48 h) of confluent cell monolayers grown in thyroid hormone-deficient medium increased the rate of uptake of [3H] 2-deoxyglucose by 2.3 +/- 0.2-fold; this effect was half-maximal at a T3 concentration of 5 nM. The uptake of the nonmetabolizable hexose [3H]3-O-methylglucose was comparably increased, confirming a stimulation of glucose transport by thyroid hormone in these cells. In addition to enhancing glucose transporter activity, T3 increased the utilization of medium glucose to a similar degree. To elucidate the mechanism of the stimulation of glucose transport by T3, the number of glucose transporter units in crude membrane preparations was quantitated by measuring the glucose-inhibitable binding of [3H]cytochalasin-B. The Kd for specific (glucose-inhibitable) binding of [3H]cytochalasin-B was 50-60 nM, a value typical for nonhepatic glucose transporters. T3 treatment caused an increase in the glucose-inhibitable binding of this ligand that was similar in magnitude to the stimulation of [3H]2-deoxyglucose uptake (2.5 +/- 0.6-fold). Northern blot analysis of total cellular RNA using a cDNA probe for the rat brain glucose transporter showed a strong 2.9-kilobase hybridization signal after stringent washing, indicating that ARL 15 cells express the specific mRNA for this type of glucose transporter. T3 treatment increased the abundance of this mRNA by 2.3 +/- 0.2-fold. It is concluded that thyroid hormone stimulates glucose transport in ARL 15 cells, which express the brain type of glucose transporter. This effect is attributable at least in part, if not entirely, to an increase in the level of glucose transporter mRNA and an accompanying increase in the number of glucose transporter units. These findings suggest that thyroid hormone may be an important regulator of glucose transporter gene expression.
我们研究了甲状腺激素对ARL 15细胞中葡萄糖转运蛋白的调控作用。ARL 15细胞是一种源自大鼠肝脏的甲状腺激素反应性细胞系。在缺乏甲状腺激素的培养基中生长的汇合细胞单层,用T3处理(5×10⁻⁸ M,处理48小时)后,[³H]2-脱氧葡萄糖的摄取速率提高了2.3±0.2倍;在T3浓度为5 nM时,这种效应达到最大值的一半。不可代谢的己糖[³H]3-O-甲基葡萄糖的摄取也有类似增加,证实甲状腺激素能刺激这些细胞中的葡萄糖转运。除了增强葡萄糖转运蛋白活性外,T3还使培养基中葡萄糖的利用率提高到类似程度。为阐明T3刺激葡萄糖转运的机制,通过测量[³H]细胞松弛素-B的葡萄糖抑制性结合来定量粗膜制剂中葡萄糖转运蛋白单位的数量。[³H]细胞松弛素-B特异性(葡萄糖抑制性)结合的解离常数(Kd)为50 - 60 nM,这是非肝脏葡萄糖转运蛋白的典型值。T3处理使该配体的葡萄糖抑制性结合增加,其幅度与[³H]2-脱氧葡萄糖摄取的刺激程度相似(2.5±0.6倍)。用大鼠脑葡萄糖转运蛋白的cDNA探针进行总细胞RNA的Northern印迹分析,经过严格洗涤后显示出强烈的2.9千碱基杂交信号,表明ARL 15细胞表达这种类型葡萄糖转运蛋白的特异性mRNA。T3处理使这种mRNA的丰度增加了2.3±0.2倍。结论是甲状腺激素刺激表达脑型葡萄糖转运蛋白的ARL 15细胞中的葡萄糖转运。这种效应至少部分(如果不是全部)归因于葡萄糖转运蛋白mRNA水平的增加以及随之而来的葡萄糖转运蛋白单位数量的增加。这些发现表明甲状腺激素可能是葡萄糖转运蛋白基因表达的重要调节因子。